Literature DB >> 9099982

Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins.

E Fonseca1, J M Nesland, J Höie, M Sobrinho-Simões.   

Abstract

The expression of simple and stratified epithelial-type cytokeratin (CK) intermediate filaments was evaluated by immunohistochemistry in a series of 41 papillary carcinomas, 10 follicular carcinomas, 2 poorly differentiated carcinomas and 34 specimens of normal thyroid parenchyma and lymphocytic thyroiditis. The aim of the study was to establish the CK profile of normal thyroid and thyroid carcinomas in order to clarify the putative application of CK immunostaining in diagnostic surgical pathology, and to evaluate whether the process of neoplastic transformation and tumour progression in the thyroid may be associated with any particular change in CK expression. Normal thyroid strongly expressed simple epithelial-type CKs 7 and 18 and, to a lesser degree, CKs 8 and 19, but did not express stratified epithelial-type CKs. The same pattern was found in lymphocytic thyroiditis, though the CK 19 immunoreactivity was stronger in these lesions than in the normal thyroid. Papillary and follicular thyroid carcinomas shared the expression of simple epithelial-type CKs 7, 8, 18 and 19. Immunoreactivity for CK 19 was frequently stronger and more widely distributed within each particular tumour in papillary than in follicular carcinomas, but it could also be detected, at least focally, in every follicular carcinoma. Strong expression of CK 19 highlighted small foci of papillary carcinoma not easily identifiable by conventional histological examination. Stratified epithelial-type CKs 5/6 and 13 were detected in a high percentage of papillary carcinomas, in contrast to their absence in follicular carcinomas and normal thyroid. The CK pattern was similar in primary and metastatic papillary carcinomas. We conclude that papillary carcinoma of the thyroid presents a distinct CK profile that may be used for diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099982     DOI: 10.1007/bf01324808

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

Review 1.  Intermediate filaments in oral neoplasia. I. Oral cancer and epithelial dysplasia.

Authors:  P R Morgan; L Su
Journal:  Eur J Cancer B Oral Oncol       Date:  1994-05

2.  Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma.

Authors:  L Hedrick; J I Epstein
Journal:  Am J Surg Pathol       Date:  1989-05       Impact factor: 6.394

3.  An immunohistochemical study of cytokeratin and vimentin in benign and malignant thyroid lesions.

Authors:  H Uchida; I Nakayama; S Noguchi
Journal:  Acta Pathol Jpn       Date:  1989-03

4.  Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma.

Authors:  L J Schelfhout; G N Van Muijen; G J Fleuren
Journal:  Am J Clin Pathol       Date:  1989-11       Impact factor: 2.493

Review 5.  Use of keratin antibodies in tumor diagnosis.

Authors:  E B Lane; C M Alexander
Journal:  Semin Cancer Biol       Date:  1990-06       Impact factor: 15.707

6.  Increased expression of cytokeratins 8, 18 and vimentin in the invasion front of mucosal squamous cell carcinoma.

Authors:  H E Schaafsma; L A Van Der Velden; J J Manni; H Peters; M Link; D J Rutter; F C Ramaekers
Journal:  J Pathol       Date:  1993-05       Impact factor: 7.996

7.  Cytokeratin patterns of liver carcinomas induced by diethylnitrosamine in monkeys.

Authors:  K Lapis; I Sarosi; J Bocsi; U P Thorgeirsson
Journal:  Lab Invest       Date:  1995-06       Impact factor: 5.662

8.  Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway.

Authors:  R Pankov; A Umezawa; R Maki; C J Der; C A Hauser; R G Oshima
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

9.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.

Authors:  R Moll; A Löwe; J Laufer; W W Franke
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

10.  High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.

Authors:  S J Raphael; G McKeown-Eyssen; S L Asa
Journal:  Mod Pathol       Date:  1994-04       Impact factor: 7.842

View more
  12 in total

1.  Difficult cases of thyroid pathology.

Authors:  Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 2.  Diagnostic role of galectin-3 in follicular thyroid tumors.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-03-04       Impact factor: 4.064

3.  A patient with primary squamous cell carcinoma of the thyroid intermingled with follicular thyroid carcinoma that remains alive more than 8 years after diagnosis.

Authors:  Tae Sik Jung; Young Lyun Oh; Young-Ki Min; Myung-Shik Lee; Moon-Kyu Lee; Kwang-Won Kim; Jae Hoon Chung
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

4.  Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Authors:  Figen Barut; Nilufer Onak Kandemir; Sibel Bektas; Burak Bahadir; Sevinc Keser; Sukru Oguz Ozdamar
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

5.  TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.

Authors:  C Eloy; J Santos; J Cameselle-Teijeiro; P Soares; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  2012-04-20       Impact factor: 4.064

6.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Roberta DePompa; Enrico Saggiorato; Armando Bartolazzi; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-07-14       Impact factor: 4.064

7.  Thyroid Solid Cell Nests: Usefulness of Cytokeratin 5/6? : Cytokeratin 5/6 in Thyroid Cell Nests.

Authors:  Adriana Handra-Luca
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 8.  Keratin expression in endocrine organs and their neoplasms.

Authors:  Peiguo G Chu; Sean K Lau; Lawrence M Weiss
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 9.  Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas.

Authors:  Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

10.  CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.

Authors:  F Noroozinia; A Gheibi; B Ilkhanizadeh; A Abbasi
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.